Zydus Lifesciences Q1 FY27 Revenue Up 22% to ₹80,170 Crore; Net Profit Down 36%
Zydus Lifesciences reported Q1 FY27 revenue of ₹80,170 crore, up 22% YoY. Net profit declined 36% to ₹9,398 crore. EBITDA was ₹19,294 crore, down 8%. The company launched its first US biosimilar, NUFYMCO™, and USFDA granted priority review for Saroglitazar Magnesium. An earnings call is scheduled for August 11, 2026.
The substantial revenue growth is positive, but the decline in net profit and EBITDA suggests potential headwinds or increased costs, moderating the overall impact.
While revenue saw significant growth, net profit and EBITDA declined year-on-year, indicating mixed performance.
Zydus Lifesciences Limited announced its unaudited financial results for the first quarter of Fiscal Year 2027 (Q1 FY27), ending June 30, 2026. The company reported a significant 22% year-on-year increase in revenue from operations, reaching ₹80,170 crore (₹801.70 billion) from ₹65,737 crore in the same period last year. This growth was driven by a strong performance across its diverse business segments.
Despite the revenue growth, the company's EBITDA for the quarter was ₹19,294 crore, a decrease of 7.6% year-on-year, with the EBITDA margin standing at 24.1%. Consequently, Net Profit for the quarter was ₹9,398 crore, marking a 35.9% decline compared to Q1 FY26. The company's R&D investments for the quarter amounted to ₹6,424 crore, representing 8% of revenues.
The Pharma business demonstrated robust growth with revenues of ₹60,900 crore, up 8.6% YoY. India Formulations saw a 19.5% increase to ₹18,158 crore, driven by outperformance in key therapies and strong brand performance. The North America formulations business registered ₹30,979 crore, a slight decrease of 3% YoY but up 5% QoQ, with new product launches and market share gains in the US generics space. The company also launched its first biosimilar in the US market, NUFYMCO™ (Ranibizumab), and completed the acquisition of Assertio Holdings.
International Markets formulations business recorded a substantial 34% YoY growth, reaching ₹9,735 crore. The API business grew by 15% to ₹1,804 crore. The Consumer Wellness segment reported significant revenue of ₹14,292 crore, up 67.2% YoY, with strong domestic and international business growth. The MedTech business registered ₹2,828 crore.
In terms of innovation, the USFDA granted priority review for Saroglitazar Magnesium for Primary Biliary Cholangitis (PBC). The company also received approval in India to initiate Phase III clinical trials for Desidustat in sickle cell disease patients. Several clinical trials for vaccines and new drug candidates are progressing across different phases.
The company announced its post-results earnings call scheduled for August 11, 2026, at 4:00 PM IST. A transcript of the conference call will be available on the company's website.
What to do with a filing like this
Zydus Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Zydus Lifesciences Limited. Read the original for the full detail.